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1. Introduction 
Rheumatoid arthritis (RA) is a common, chronic, inflammatory disease. It affects around 1% 
of the adult population in all age groups, although the incidence peaks during the fifth 
decade of life. The aetiology of RA is unknown, but it is considered to be autoimmune in 
nature. Inflammation in the synovial tissues of the joints is the hallmark of RA, causing pain, 
stiffness, loss of function and progressive destruction of the cartilage and bone in the 
inflamed joints in the majority of patients. Early diagnosis and appropriate treatment is 
crucial for the amelioration of symptoms, improvement of function and prevention of 
structural damage.  
Traditionally, treatment of RA has been based on the use of a group of disease-modifying 
antirheumatic drugs (DMARDs), of which methotrexate (MTX) is the most widely used, 
often in combination with corticosteroids and/or NSAIDs (non-steroid anti-inflammatory 
drugs). Leflunomide, sulphasalazine, azathioprine, are examples of other synthetic 
DMARDs. The landscape of RA treatment has changed dramatically during the last decade 
due to the introduction of biologic DMARDs, small molecules that target small molecules 
(like cytokines) and cells of the immune system, important mediators of the immunological 
mechanisms in RA. To date, nine biologic agents have been approved for the treatment of 
RA and more molecules with distinct mechanisms of action are currently being tested in 
laboratories and in clinical trials. The good efficacy and general safety of these agents is well 
established from both clinical and epidemiological trials, but there are still several issues 
that remain unclear or need further study, such as long-term safety, more individualized 
treatment by finding predictors of response, cost-effectiveness, when to introduce biologic 
treatment and the feasibility of discontinuation after achieving low disease activity or 
remission.  
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Biologic 
(generic name) 
Adalimumab Certolizumab 
pegol 
Etanercept Golimumab Infliximab 
Brand name Humira Cimzia Enbrel Simponi Remicade 
Structure monoclonal 
antibody, fully 
humanized 
PEGylated 
Fab’ fragment 
of humanized 
anti-TNF 
monoclonal 
antibody 
Dimerized 
soluble TNF 
receptor 
monoclonal 
antibody, 
fully 
humanized 
Chimeric 
anti-TNF 
monoclonal 
antibody 
Mechanism of 
action 
TNF inhibition 
Approved 
dosage 
40 mg 200 mg 50 mg 50 mg 3 mg/kg 
Approved 
interval 
every 2 weeks every 2 weeks once weekly once monthly every 8 
weeks 
Route of 
administration 
Subcutaneous Subcutaneous Subcutaneous Subcutaneous Intravenous 
Biologic 
(generic name) 
Abatacept Anakinra Rituximab Tocilizumab  
Brand name Orencia Kineret MabThera 
(Rituxan) 
RoActemra 
(Actemra) 
 
Structure Dimerized 
CTLA4 
molecule 
Recombinant 
IL-1 receptor 
antagonist 
Chimeric 
anti-CD20 
monoclonal 
antibody 
Humanized 
anti-IL-6 
receptor 
antibody 
Mechanism of 
action 
Inhibits T-cell 
activation 
Binds IL-1 
receptor 
Binds and 
eliminates B 
cells 
Binds IL-6 
receptor 
Approved 
dosage 
500–1000 mg 100 mg 1000 mg x 2 
(with 2 weeks 
interval) 
8 mg/kg 
Approved 
interval 
once monthly once daily every 6–12 
months 
once monthly
Route of 
administration 
Intravenous Subcutaneous Intravenous Intravenous 
Table 1. Biologic agents approved for the treatment of rheumatoid arthritis (RA).  
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2. Biologic agents 
TNF (tumor necrosis factor) is a key cytokine of the immune response. Analysis of cytokine 
mRNA and protein in rheumatoid arthritis tissue revealed that many proinflammatory 
cytokines such as TNF alpha, IL-1 and IL-6 are abundant in all patients regardless of 
therapy1. These cytokines are of major importance in rheumatoid arthritis and are 
therapeutic targets. Five TNF inhibitors have been approved for the treatment of RA: the 
monoclonal antibodies infliximab (chimeric), adalimumab and golimumab (fully human), 
the TNF receptor etanercept, and the PEGylated Fab fragment of a fully human anti-TNF 
monoclonal antibody certolizumab pegol. There are several differences in 
pharmacodynamics and pharmacokinetics between these agents (table 1). Apart from the 
TNF inhibitors, biologics with different mechanism of action have been increasingly used in 
the clinical practice. Rituximab targets CD20 on the surface of B-cells and have been widely 
used in hematology for lymphoma treatment; Tocilizumab is an IL-6 (interleukin 6) inhibitor 
while anakinra blocks IL-1. Finally, abatacept inhibits costimulation of T-cell by binding B7 
(table 1). 
3. Efficacy of biological DMARDs 
Numerous randomized clinical trials provide clear evidence on the efficacy of biologic 
agents in RA, both in early disease (short disease duration) in biologic-naïve population and 
in late RA (longer disease duration) after failure of traditional DMARDs. These trials show 
the superiority of combination treatment of a biologic agent with methotrexate versus 
methotrexate monotherapy in both early and late disease2-18. In figure 1 and 2 the ACR 20, 50 
and 70 responses* of TNF inhibitors and other biologics from the largest clinical trials in 
methotrexate naïve patients and after inadequate response to methotrexate, are shown. The 
data demonstrate also clearly, especially in the MTX-naïve population, that a considerable 
proportion of patients respond to the simpler and less expensive monotherapy with 
methotrexate (MTX). Thus, one should keep in mind that in the combination groups, there 
are patients who would have responded to MTX monotherapy as well. 
In figure 2, the clinical responses of other biologic agents plus MTX versus placebo plus 
MTX are summarized. Again efficacy in early and in late disease is evident. Superiority of 
rituximab over placebo was observed in the IMAGE and SERENE trials9,10. Abatacept 
demonstrated acceptable safety and clinically meaningful efficacy in methotrexate naïve 
patients and methotrexate non responders7,11. Additionally, in the TOWARD trial17, 
tocilizumab-treated patients achieved significantly better results than those who received 
placebo during the first 6 months of therapy, after inadequate response to traditional 
                                                                                    
* ACR responses is a validate tool for the evaluation of efficacy of treatment in RA. ACR 20/50/70 response is defined as 
at least 20, 50 or 70%, respectively, improvement in both swollen joint count (SJC) and tender joint count (TJC), and at 
least 20, 50 and 70% improvement in 3 of the 5 following measures: pain VAS (visual analogue scale), Patient global 
assessment, Physician global assessment, ESR (erythrocyte sedimentation rate) or CRP (C-reactive protein) and 
functional questionnaire.  
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DMARDs. A large trial on the efficacy of tocilizumab in early RA is currently conducted. All 
these biologic agents seem to have comparable efficacy and significantly greater efficacy 
than placebo.  
 
Figure 1. A and B. Efficacy of TNF inhibitors (infliximab INF, etanercept ETA, adalimumab ADA, 
golimumab GLM, certolizumab pegol (CER) in combination with methotrexate (MTX) versus MTX 
monotherapy in MTX-naïve RA patients (1A) and RA patients with an inadequate response to MTX 
(1B). Efficacy is assessed by ACR 20, 50 and 70 responses.  
4. Safety of biological DMARDs 
Extension phase of clinical trials as well as data from registry studies provide us with 
important information about the safety of biologic DMARDs. The safety profile is generally 
acceptable, with a small increase risk for infections being the most common adverse event2-
22. Reactivation of latent tuberculosis is a well known risk during treatment with TNF 
inhibitors, therefore screening for tuberculosis is recommended before initiation of a TNF 
inhibitor. Infusion reaction is a common adverse event for rituximab and infliximab. Anti-
TNF induced SLE and demyelinating disease are rare complications of TNF inhibitors. 
Regarding risk for malignancies, data so far have not shown any clear increase in risk for 
malignancies. A meta-analysis of clinical registries and prospective observational studies 
showed no increase in malignancies other than skin cancers, including lymphoma, 
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associated with the use of TNF inhibitors23. However, longer follow up especially from large 
cohorts of patients, is needed.  
 
Figure 2. A and B. Efficacy of rituximab (RTX), abatacept (ABA) and tocilizumab (TOC) in combination 
with methotrexate (MTX) versus MTX monotherapy in MTX-naïve RA patients (2A) and RA patients 
with an inadequate response to MTX (2B). Efficacy is assessed by ACR 20, 50 and 70 responses.  
5. When to start biologic agents 
The effectiveness of biologic agents is well established in the above large, randomized clinical 
trials. These results do not, however, answer the question of when a biologic DMARD should 
be initiated. Traditional DMARDs, and most often methotrexate, unless contraindicated) is the 
first line treatment. However, about two third of patients who start treatment with 
methotrexate will discontinue treatment for reasons of either inefficacy or intolerance. The next 
step is either a combination of synthetic DMARDs (e.g. sulphasalazine and  
hydroxychloroquine) or introduction of a biologic agent. So far, only a few clinical trials have 
made a direct comparison of these two treatment options. In the SWEFOT trial, patients with 
early RA with an inadequate response to MTX after 3 months, defined as lack of achievement 
of low disease activity, were randomly allocated to addition of either sulphasalazine and 
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hydroxychloroquine or infliximab. The latter group had significantly greater responses after 12 
months of therapy, with 39% of patients achieving the primary endpoint (European League 
Against Rheumatism (EULAR) good response†, which is a widely used validated outcome) 
compared to 25% in the former group (p=0.016)24. However, at the 2-year follow-up 
assessment, the clinical difference was no longer present (EULAR Good response was 38% in 
infliximab group vs. 31% in the conventional DMARDs group (p=0.2), but radiological disease 
progression was significantly greater in the latter group than the former25.  
Similar results were established in the BeSt trial26,27. In the BeSt trial three treatment groups 
were formed: sequential DMARD monotherapy (group 1), step-up combination therapy 
(group 2), initial combination therapy with tapered high-dose prednisolone (group 3) and 
infliximab (group 4). It was shown that a more aggressive treatment strategy as in group 3 
and 4 provided earlier clinical improvement than a less aggressive strategy as in groups 1 
and 2. Low disease activity (defined by DAS44 ≤ 2.4) was reached by 53%, 64%, 71% and 74% 
of patients in group 1, 2, 3 and 4, respectively (p=0.0004 for group 1 vs. 3, p=0.001 for group 
1 vs. 4). After 2 years, patients in all four treatment groups had approximately the same 
improvement in disease activity and functional status irrespective of initial treatment, 
probably because of tight control and frequent treatment adjustments. However, the more 
aggressively treated patients had less radiological progression of joint damage, and during 
the second year more of them could be treated successfully with monotherapy, suggesting 
that the initial aggressive therapy did result in some long-term gains.  
6. When to stop biologic agents 
A significant number of patients who receive biological treatment achieve low disease activity 
or remission. It is often difficult to define these terms, and there are today several definitions of 
both low disease activity and remission. According to the 2011 ACR (American College of 
Rheumatology) / EULAR (EUropean League Against Rheumatism) criteria, remission of 
rheumatoid arthritis is defined as tender joint count ≤ 1 AND swollen joint count ≤ 1 AND C-
reactive protein ≤ 1 mg/dl AND patient global assessment ≤ 1 (on a 0-10 scale) (boolean-based 
definition) or a Simplified Disease Activity Index score of ≤ 3.3 (Index-based definition)28. 
Other definitions of low disease activity and remission are also frequently used, as for example 
DAS28 score ≤ 3.2 (low disease activity) and DAS28 ≤ 2.6 (remission).  
When a patient is in state of low disease activity or remission for a sufficiently long period 
of time (usually at least 6 months) the next step is to assess the feasibility of discontinuation 
of the biologic agent with the aim of maintaining the good clinical response. This is a 
                                                                                    
† Definition of EULAR responses:  
 Improvement in DAS28 from baseline
DAS28 at endpoint ≥1.2 >0.6 and <1.2 ≤0.6 
≤3.2 GOOD MODERATE NO 
>3,2  and ≤5.1 MODERATE MODERATE NO 
>5.1 MODERATE NO NO 
DAS28=Disease Activity Score (based on 28 joint status) 
DAS28= 0.56* ඥ܂۸۱૛ૡ	 + 0.28* ඥ܁۸۱૛ૡ	+ 0.70*ln (ESR) + 0.014* (General Health) 
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question of importance for reasons of safety and health economics. In various settings, the 
possibility has been investigated of discontinuing the biologic agent while maintaining the 
patient in remission on a conventional DMARD.  
In the ATTRACT study 17 patients in a single centre in the UK received infliximab and all 17 
experienced flare-ups after discontinuation of the biologic therapy after 2 years, with a mean 
time of 13.5–15.0 weeks after the end of therapy29. Of importance, re-introduction of infliximab 
after disease flare was associated with comparable responses without any safety issues. In 
another study Quinn et al. addressed the same question in a randomized, double-blind, 
placebo-controlled trial in a population of patients with early RA, with symptom duration of 
<12 months2. Induction of remission with infliximab plus MTX in early, poor prognosis RA 
provided not only significant reduction in synovitis and erosions at 1 year (shown by magnetic 
resonance imaging), but also sustained functional and quality-of-life benefits for 70% of the 
patients at 2 years despite infliximab withdrawal. These two studies tested the same question 
in different populations of RA patients; the former one in patients with longstanding disease 
(mean disease duration, 11 years), and the latter in patients with early RA. More recently, 
Tanaka et al. determined the possibility of discontinuing infliximab after attaining DAS-
guided low disease activity in patients with RA in the remission induction by Remicade in RA 
(RRR) study30. Of 102 patients, 56 (55%) maintained DAS28<3.2 and 44 (43%) reached 
remission (DAS28<2.6) 1 year after the discontinuation of infliximab. The mean disease 
duration in this study was 5.9 years which suggests that discontinuation of infliximab would 
be possible not only in patients with early RA but also in patients with more established 
disease. In a post hoc analysis from the BeSt study, it was shown that significantly more 
patients who received initial combination therapy with infliximab and MTX achieved 
sustained DAS44≤2.4 and were able to discontinue infliximab, compared with those with 
delayed introduction of the biologic agent (56% vs. 29%, p=0.008)31,32. It was also shown in the 
BeSt study that the shorter the symptom duration, the higher the likelihood of a biologic-free, 
and even a drug-free, remission. A systematic review and meta-analysis showed that patients 
with established RA who stopped treatment with traditional DMARDs had a significantly 
higher risk of disease flare or deterioration than those who continued treatment33. In this 
analysis, however, patients had RA of more than 2 years duration. Larger randomized, 
controlled, double-blind trials are needed in order to better approach this important issue.  
Several conclusions can be drawn from the information that exists today about 
discontinuation of biologic DMARDs:  
- Discontinuation of biologic treatment and sustained remission or low disease activity is 
the long-term therapeutic goal, important for matters of long-term safety and health 
economics.  
- Biologic-free remission may be possible after achieving remission or low disease 
activity in a considerable proportion of patients.  
- The duration of disease until the introduction of the biologic treatment may be 
negatively associated with the risk of deterioration after discontinuation of treatment, 
thus suggesting that earlier initiation of biologic treatment leads not only to better 
results, but also increases the possibility of withdrawal of biologic agents with 
maintenance of remission.  
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- More data about the feasibility of dose reduction or discontinuation of biological 
DMARDs are needed.  
7. Principles for use of biologic treatment in rheumatoid arthritis 
The rapid progress and advances in the field of biologic treatment in RA, combined with the 
high cost of these drugs and the potential long-term safety issues, makes it necessary to 
define clear rules that will guide the use of these agents in clinical practice.  
The rheumatologist should always keep in mind that the goal of RA treatment today is 
remission or low disease activity, if remission cannot be achieved. Treatment efficacy should 
be assessed in tight time intervals and changes in treatment should be considered if the goal 
has not been reached34.  
As soon as the diagnosis of RA is established a synthetic DMARD (most often Methotrexate) is 
started with or without concomitant corticosteroids. If the goal of treatment is not achieved 
after 3 months, an additional DMARD can be added or a biologic agent can be introduced. As 
it was analyzed above, data have shown superiority of the latter choice. Especially for patients 
with multiple negative prognostic factors, such as seropositivity, radiographic progression and 
high disease activity, early aggressive treatment is strongly indicated. In the absence of these 
unfavorable factors one could consider testing switching of synthetic DMARD or combination 
of synthetic DMARD +/- corticosteroids before biologics. In patients with active RA who have 
not yet been treated with DMARDs there is strong evidence that biologics provide better 
results at the group level, but not widely used in practice based on various considerations 
(safety, high cost, possibility of very good effect of methotrexate).  
The first biologic agent is most often a TNF inhibitor, unless contraindicated. If possible, 
TNF inhibitors should be combined with MTX; the clinical efficacy particularly the 
radiological efficacy of the combination is clearly superior to TNF inhibitor monotherapy. In 
case of a contraindication to TNF inhibitor therapy, a biologic agent with a different 
mechanism of action (rituximab, abatacept or tocilizumab) can be chosen.  
About one third of patients will discontinue the first TNF inhibitor for reasons of either 
intolerance or inefficacy (lack of efficacy or loss of efficacy). Since the goal is still remission, 
even patients with moderate responses (‘partial responders’) should eventually be 
candidates for an alternative treatment.  
After the failure of one biologic agent for the reasons described above, and after having 
perhaps tried to modify the dose of the concomitant DMARDs and/or corticosteroids with 
no effect, three main treatment options are available: a) optimize the dose of biologic drug; 
b) switch between TNF inhibitors; or c) switch to a biologic agent with a different 
mechanism of action. 
7.1. Optimize dose of biologic 
As it is shown in table 1, the TNF inhibitors have different dose intervals, ranging from once 
weekly (etanercept) to once every 8 weeks (infliximab). Concerning optimization of the 
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infliximab dose, controversial data are available. In the ATTRACT trial, four different 
treatment regimens of infliximab were studied:  infliximab 3 mg kg−1 every 4 and 8 weeks 
and 10 mg kg−1 every 4 and 8 weeks. At 24 weeks similar American College of 
Rheumatology (ACR) responses were observed. At 48 weeks, however, there was a 
tendency for the lowest dosage of infliximab to be less effective than the higher ones, but 
this difference was only significant with respect to the ACR50 responses29.  
An important question is whether dose increase or change of treatment interval can yield 
better results in patients with secondary loss of efficacy to infliximab. Results from 
uncontrolled observational studies have suggested that this might be true35. On the other 
hand, in a double-blind randomized trial, Pavelka et al. showed no significant difference in 
efficacy of two dosages of infliximab (3 and 5 mg/kg) after initial failure of the lower dosage 
to lead to remission36. Moreover, the higher dosage had a poorer safety profile. In an 
observational study conducted in our centre, patients in whom the dose of infliximab was 
increased in clinical practice appeared to have a benefit, as defined by reduction in the 
disease activity score (DAS28)37. However, patients in the control groups (i.e. patients with 
no change in infliximab dose and those receiving a stable dose of etanercept) also showed an 
improvement in DAS28. This observation suggests that the improvements were most 
probably attributable to regression to the mean and that no important benefit is gained from 
dose increases of infliximab. Finally, van den Bemt et al. found that 17 of 18 patients who 
were in clinical practice treated with infliximab at dosages higher than 3 mg/kg showed no 
deterioration of their RA if the dosage was reduced to 3 mg/kg38. In conclusion, the evidence 
suggests that increasing the dose of infliximab might result in loss of time, higher cost and 
potentially more side effects with no significant efficacy gain in most patients. Therefore, it 
would clearly be useful to be able to identify, using relevant biomarkers, a smaller subset of 
patients who might truly benefit from dose increases. Studies to investigate this possibility 
are currently underway. 
7.2. Switching to an alternative TNF inhibitor 
As it is shown in table 1, there are substantial differences between the five TNF inhibitors 
available today (in molecular structure, immunological actions and in pharmacokinetics). This 
is the reason why switching from one TNF inhibitor to another does make sense and is often 
used in the clinical practice, although these agents target the same cytokine. Observational 
studies support this argument, as a significant proportion of patients benefit from this 
switching. In the randomized double-blinded GO-AFTER study, patients who received 
golimumab after failure of a prior TNF inhibitor, showed significantly greater responses than 
those who received placebo39. However, cohort study data have shown a gradual loss of 
efficacy after a greater number of switches40-44. Thus, a first switch might provide significant 
improvement, whereas the effect is much less profound at the second or third switch. 
7.3. Switch to a biologic with different mechanism of action 
It might sound more reasonable, after the failure of TNF inhibition the next step to be 
change of mechanism, rather than switching between agents of the same drug class. There is 
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strong evidence about the efficacy of rituximab, abatacept and tocilizumab after TNF 
treatment (figure 2). However, there is no randomized clinical trial comparing head to head 
these two treatment options, but there are some observational studies from national 
registries. In the Swiss Clinical Quality Management program for RA (SCQM-RA) registry, 
patients with inadequate response to TNF inhibitor treatment achieved greater reductions in 
DAS28 when switching to rituximab than to an alternative TNF blocker45. This was 
especially obvious when the reason for discontinuation of the previous TNF inhibitor was 
secondary inefficacy46. A small observational study by Venkatachalam et al. provided similar 
results, whilst a study reported by Buch et al. also demonstrated comparable results of 
rituximab and alternative TNF inhibitors47,48. Our data have shown slightly better overall 
results for patients who had failed TNF inhibitor therapy when treated with rituximab than 
with another TNF blocker, but both options provided clinical benefits49.  
In figure 3 an algorithm of biologic treatment in RA is presented50.  
 
Failure*: primary or secondary loss of efficacy, intolerance or a partial, inadequate response.  
(After optimizing DMARD dose and/or trying combination of DMARDs). 
Figure 3. Algorithm of biologic treatment in RA.  
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8. Conclusions 
The field of RA treatment has changed dramatically after the introduction of biologic 
DMARDs. Despite the advances though, several issues remain to be further studied and 
clarified. On the one hand treatment algorithms are needed of the choice and time of 
introduction of biologics. On the other hand a more individualized treatment might be 
possible in the future. Such an approach is crucial, taking into consideration the increasing 
number of biologic agents, their high cost and the importance of choosing the right 
treatment from the beginning. These are some of the important challenges of clinical, 
epidemiological and basic rheumatologic research.  
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